Wegovy pharma facts: who makes it, what the evidence shows, and how it reaches UK patients

The STEP 1 trial: what Novo Nordisk's own phase 3 data showed

Novo Nordisk's pivotal STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and enrolled adults with obesity but without type 2 diabetes. Participants using semaglutide 2.4 mg weekly achieved an average body-weight reduction of around 15%, compared with roughly 2.4% in the placebo group. That figure is the anchor for every subsequent conversation about what pharma semaglutide can deliver, and it matters because it comes from a rigorous, peer-reviewed trial, not a manufacturer's press release.

What STEP 1 also confirmed is that the weight loss was sustained over the trial period when treatment continued, and that the most common adverse effects were gastrointestinal: nausea, diarrhoea and constipation led the list, concentrated around dose increases and typically settling within a few weeks. Understanding the pharma background here is genuinely useful, it explains why the titration schedule exists and why your prescriber will not simply start you on the highest dose.

Novo Nordisk has since submitted further evidence to regulators on a higher 7.2 mg dose. If you want to explore the full semaglutide picture, our semaglutide overview covers the mechanism and approved indications in more depth.

Novo Nordisk's UK authorisations: what Wegovy is and isn't licensed for

Wegovy's UK marketing authorisation covers weight management alongside a reduced-calorie diet and increased physical activity. The MHRA (not the EMA) is the licensing authority for UK medicines. Novo Nordisk secured MHRA approval for Wegovy on the back of the STEP programme, and NICE appraised semaglutide in TA875, recommending it for use within specialist weight management services for a maximum of two years, for adults meeting the BMI and comorbidity thresholds set out in that guidance.

It is worth being precise about the company's other semaglutide products. Ozempic is also made by the same pharma company behind Wegovy and contains the same active molecule, but its UK licence covers type 2 diabetes management, it has never been authorised by the MHRA for weight loss, and prescribing it for that purpose is off-label. Rybelsus is Novo Nordisk's oral semaglutide tablet, again licensed for type 2 diabetes only. The confusion between these products is common enough that our page on what Wegovy is addresses it directly.

The January 2026 MHRA approval of a 7.2 mg maintenance dose, followed by the 14 April 2026 approval of a dedicated single-dose 7.2 mg pen, extended Novo Nordisk's authorised schedule for Wegovy further. That pen carries a BMI-of-30-or-above criterion and is not approved for the cardiovascular indication. The titration path still begins at 0.25 mg, the pen format changes, the clinical process does not.

Supply chain, genuine stock and what actually arrives at your door

Because Wegovy is a prescription medicine supplied through the licensed UK pharmaceutical supply chain, it must originate from an MHRA-authorised route. Novo Nordisk produces the medicine; it moves through licensed wholesalers to GPhC-registered pharmacies; your prescriber issues a UK prescription; the pharmacy dispenses and ships. That chain matters more than it might seem, because the MHRA has documented substantial quantities of counterfeit weight-loss pens circulating online, fake products seized in raids across the UK, some containing hazardous substances. The safe route is a pharmacy you can verify on the GPhC register.

At nume, medicines are sourced through Novo Nordisk's authorised UK supplier relationships. Once a prescriber approves your treatment, DPD delivers to your door the next working day, plain, unbranded box, tracked link on your phone, the pen inside cold-packed and ready for the fridge. No guesswork about provenance. If you're unsure where to obtain a legitimate supply, our guide on where to buy Wegovy in the UK explains the options and the red flags to avoid.

Some searches for pharma semaglutide also surface names that are not Novo Nordisk's branded product. Pages on raw pharma semaglutide or compounded semaglutide from non-licensed sources describe products that fall outside the UK's licensed supply chain; they are not the same medicine as Wegovy, and no UK-registered pharmacy can legally dispense them for weight management.

Eligibility, cost context and the consultation step

Wegovy's licensed eligibility thresholds in the UK are a BMI of 30 or above, or 27–29.9 where at least one weight-related condition is present (such as high blood pressure, raised cholesterol or obstructive sleep apnoea). Lower BMI thresholds (2.5 kg/m² below the standard figures) apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, reflecting adjusted health-risk evidence. A prescriber reviews the complete picture, not the BMI figure alone; conditions that would make treatment unsuitable, including a personal or family history of certain thyroid cancers, are assessed at consultation. You can read more about the full eligibility criteria on our weight-loss treatments overview.

On the NHS, Wegovy is available through specialist weight management services under the NICE TA875 criteria, though waiting lists are commonly long and the qualifying thresholds are strict. Private prescribing through a regulated online pharmacy gives access without a referral, subject to clinical suitability. Cost for private treatment has shifted: Eli Lilly's September 2025 price increase for Mounjaro changed the broader private market context, and Wegovy's pricing varies by dose and provider, typically in the range reported since mid-2025. Price is a reasonable question; for a prescription medicine, it isn't the only one. Our clinical team's profile is at our prescribers page if you want to know who reviews consultations.

If you have questions before starting, our FAQs cover the most common queries our prescribers receive. Ready to find out whether Wegovy is clinically suitable for you? Speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.